Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Genentech stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00
Sep 25, 2026

Genentech inks $1.5 billion bispecific antibody deal with Earendil Labs

Roche's Genentech is paying Earendil Labs $55 million upfront in a research collaboration to discover and develop multiple bispecific antibody cancer therapies. The oncology-focused deal includes milestone payments that could bring its total value to over $1.5 billion.

Sep 25, 2026·4 sources
00
Apr 7, 2026

FDA Supports Proposals to Incentivize Domestic Drug Manufacturing

The FDA has backed proposals in the Trump administration's budget aimed at encouraging pharmaceutical companies to test and manufacture drugs domestically, including potential tariffs and incentives.

Apr 7, 2026·2 sources
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

Topics

Cancer & OncologyCancer and Cancer TreatmentDrug safetyTargeted cancer therapyCancer treatmentDrug Policy, Pricing & ApprovalClinical trialsPharmaceutical IndustryFDA drug approvalDrug Approval and Clinical TrialsPharmaChina trade strategyGlobal supply chainsU.S.–China relationsNearshoring & reshoring

Related entities

United StatesSwitzerlandNew YorkChina